J&J brushes off concerns over talc, opioid and Risperdal litigationJohnson & Johnson has brushed off investors’ concerns over the many lawsuits it is facing, saying its legal Share XJ&J brushes off concerns over talc, opioid and Risperdal litigationhttps://pharmaphorum.com/news/jj-brushes-off-concerns-over-litigation/
US court tells J&J to pay $8bn damages to man over breast growthA court has told Johnson & Johnson to pay $8 billion in punitive damages to a man who Share XUS court tells J&J to pay $8bn damages to man over breast growthhttps://pharmaphorum.com/news/us-court-tells-jj-to-pay-8bn-damages-to-man-over-breast-growth/
Making behaviour change stickBehaviour change is set to become a key skill for pharma companies in the very near future – Share XMaking behaviour change stickhttps://pharmaphorum.com/digital/making-behaviour-change-stick/
The science of prevention‘Prevention’ might be the buzzword of the moment in the pharma industry, but what does it actually mean Share XThe science of preventionhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-science-of-prevention/
Teva settles Oklahoma opioid lawsuit ahead of trialTeva has opted to settle the first trial among hundreds of cases that accuse it and other drugmakers Share XTeva settles Oklahoma opioid lawsuit ahead of trialhttps://pharmaphorum.com/news/teva-settles-oklahoma-opioid-lawsuit-ahead-of-trial/
Shifting the paradigm from “disease care” to health careCat Oyler, vice president, global public health, tuberculosis at Johnson & Johnson, explains that by shifting focus to Share XShifting the paradigm from “disease care” to health carehttps://pharmaphorum.com/views-and-analysis/shifting-paradigm-disease-care-health-care/
Once-a-month HIV treatment sees promising phase III resultsJanssen and ViiV have reported positive data for their once-monthly injectable HIV combo regimen in two phase III Share XOnce-a-month HIV treatment sees promising phase III resultshttps://pharmaphorum.com/news/once-a-month-hiv-treatment-sees-promising-phase-iii-results/
Johnson & Johnson: Partnering to eliminate diseaseJ&J’s global head of external innovation communication on how partnerships are fuelling the company’s vision for a World Share XJohnson & Johnson: Partnering to eliminate diseasehttps://pharmaphorum.com/views-and-analysis/johnson-johnson-partnering-to-eliminate-disease/
J&J pays $3.4 billion for robotics firm AurisJohnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that Share XJ&J pays $3.4 billion for robotics firm Aurishttps://pharmaphorum.com/news/jj-pays-robotics-firm-auris/
